Characteristics and management of patients with SARS‐CoV2 infection admitted to pediatric intensive care units: Data analysis of the Spanish national multicenter registry

INTRODUCTION The purpose of this study is to describe the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) disease characteristics and management in children admitted to the pediatric intensive care units (PICU). METHODS The present study was based on a national multicentric prospective registry including PICU patients with SARS-CoV2 infection or symptoms of multisystem inflammatory syndrome in children (MIS-C). RESULTS A total of 298 patients were admitted to 41 different Spanish PICUs. A total of 76% of them were previously healthy. The most frequent manifestation was MIS-C (69.8%). On admission, 59.4% of patients did not have respiratory distress, and only 17.4% needed conventional mechanical ventilation (MV). The need for MV was associated with age (incidence rate ratios [IRR] 1.21, p < .012), pediatric sequential organ failure assessment score (p-SOFA) Score (IRR 1.12, p = .001), and need for transfusion (IRR 4.5, p < .004) in MIS-C patients, and with vasoactive drug use (IRR 2.73, p = .022) and the diagnosis of acute respiratory distress syndrome (IRR 2.83, p = .018) in patients admitted for other reasons. During the first day of admission, 56% of patients met shock criteria and 50.7% needed vasoactive drugs. In MIS-C patients, their use was associated with higher p-SOFA score (IRR 1.06, p < .001) and with the diagnosis of shock (IRR 5.78, p < .001). In patients without MIS-C, it was associated with higher p-SOFA score (IRR 1.05, p = .022). The mortality rate was 3%, being lower in MIS-C patients compared to patients admitted for other reasons (0.5% vs. 9.4%, p < .001). It was also lower in previously healthy patients compared to patients with previous comorbidities (0.9% vs. 9.7%, p < .001). CONCLUSIONS Severe SARS-CoV2 infection is uncommon in the pediatric population. In our series, respiratory distress was rare, being MIS-C the most frequent cause of PICU admission related to SARS-CoV2. In most cases, the course of the disease was mild except in children with previous diseases.

[1]  A. Randolph,et al.  Treatment of Multisystem Inflammatory Syndrome in Children: Understanding Differences in Results of Comparative Effectiveness Studies , 2022, ACR open rheumatology.

[2]  Bryant J. Webber,et al.  Characteristics and Clinical Outcomes of Children and Adolescents Aged <18 Years Hospitalized with COVID-19 — Six Hospitals, United States, July–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[3]  E. Liu,et al.  Potentially effective drugs for the treatment of COVID-19 or MIS-C in children: a systematic review , 2021, European Journal of Pediatrics.

[4]  J. Meek,et al.  Risk Factors for Severe COVID-19 in Children. , 2021, Pediatrics.

[5]  Manish M Patel,et al.  Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[6]  Manish M Patel,et al.  Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2 , 2021, JAMA network open.

[7]  A. Chokkalingam,et al.  Compassionate Use of Remdesivir in Children With Severe COVID-19 , 2021, Pediatrics.

[8]  Manish M Patel,et al.  Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. , 2021, JAMA.

[9]  A. Belot,et al.  Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. , 2021, JAMA.

[10]  J. Nagaraj,et al.  Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives , 2021, Clinical Epidemiology and Global Health.

[11]  I. Jordan,et al.  Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain , 2020, Critical Care.

[12]  S. Ley,et al.  COVID‐19 in childhood: Transmission, clinical presentation, complications and risk factors , 2020, Pediatric pulmonology.

[13]  A. García-Salido,et al.  Documento español de consenso sobre diagnóstico, estabilización y tratamiento del síndrome inflamatorio multisistémico pediátrico vinculado a SARS-CoV-2 (SIM-PedS) , 2020, Anales de Pediatría.

[14]  Sohan Seth,et al.  Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study , 2020, BMJ.

[15]  I. Bassett,et al.  Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses , 2020, The Journal of Pediatrics.

[16]  M. Antonelli,et al.  Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. , 2020, JAMA internal medicine.

[17]  I. Jordan,et al.  A multicenter national survey of children with SARS-CoV-2 infection admitted to Spanish Pediatric Intensive Care Units , 2020, Intensive Care Medicine.

[18]  B. Scholefield,et al.  Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital , 2020, Pediatric Cardiology.

[19]  P. Davies,et al.  Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. , 2020, JAMA.

[20]  M. Priestley,et al.  Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. , 2020, JAMA pediatrics.

[21]  A. Tagarro,et al.  Screening and Severity of Coronavirus Disease 2019 (COVID-19) in Children in Madrid, Spain. , 2020, JAMA pediatrics.

[22]  R. Jin,et al.  Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China , 2020, Current Medical Science.

[23]  J. Ramos,et al.  Recomendaciones sobre el manejo clínico de la infección por el «nuevo coronavirus» SARS-CoV2. Grupo de trabajo de la Asociación Española de Pediatría (AEP) , 2020, Anales de Pediatría.

[24]  OUP accepted manuscript , 2021, Journal of the Pediatric Infectious Diseases Society.

[25]  Jérémie F. Cohen,et al.  Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study , 2020, BMJ.

[26]  Multisystem In fl ammatory Syndrome in Children: An International Survey , 2022 .